摘要
目的初步评估探讨核酸筛查模式对献血人群乙型肝炎病毒(hepatitis B virus,HBV)传播残余风险度的影响。方法采用中国大陆执业比对工作组信息管理系统的相关数据,利用NAT单阳性率-窗口期比率数学模型(NAT yield/WP ratio model),对2015—2019年度我国18家血液中心的献血人群HBV传播的残余风险度进行趋势分析;同时分析比较2019年18家血液中心的ELISA联合核酸单检/混检(ELISA+ID-NAT/MP-NAT)和ELISA联合核酸混检(ELISA+MP-NAT)2种血液筛查(简称血筛)模式对残余风险度的影响。结果18家血液中心5年的HBV血筛残余风险度总体趋势经趋势卡方检验显示:核酸检测单阳性率趋势χ^(2)=39.42(P<0.01),残余风险度趋势χ^(2)=279.792(P<0.01);ELISA+ID-NAT/MP-NAT和ELISA+MP-NAT 2种不同血筛模式对残余风险度RR的影响差异有显著统计学意义,卡方检验显示χ^(2)=7.4(P<0.01)。结论自2015年我国将核酸检测用于血筛以来,HBV输血传播的残余风险度呈逐年下降趋势,目前主要的2种血筛模式对血液残余风险度有可能造成差别。
Objective To preliminarily estimate and study the effect of nucleic acid testing in blood screening on the residual risk(RR)of transfusion transmitted HBV infection(TTI HBV).Methods Using the NAT yield/WP ratio model and adopting the relevant data of information management system of practice comparison working party in the Mainland of China,this paper analyzed the trend of the RR of TTI HBV among 18 blood centers from 2015 to 2019 in China,and compared the impact of two kinds of blood screening strategies which were ELISA+ID-NAT/MP-NAT(individual-donation nucleic acid testing or mini-pool nucleic acid testing)and ELISA+MP-NAT on RR in 2019.Results The overall trends of the 5-year RR of HBV among 18 blood centers showed by trend chi square test were NAT single positive rate trendχ^(2)=39.42(P<0.01)and residual risk trendχ^(2)=279.792(P<0.01);The influence on RR from the differences of ELISA+ID-NAT/MP-NAT and ELISA+MP-NAT was statistically significant,and chi square test showed thatχ^(2)=7.4(P<0.01).Conclusions Since the implementation of nucleic acid testing in the blood screening in China from 2015,the residual risk of transfusion transmitted HBV infection has decreased year by year.The observed two blood screening strategies which dominated in China may lead to discrepancy in the residual risk of TTI.
作者
黄敏
白林
卢长春
朱姗姗
李玉军
张志安
马海莉
尤榕
秦䶮丽
居兵
韩卫
王芳
陈雪
袁晓华
任星历
赵磊
张铃浩
易星
邱艳
Huang Min;Bai Lin;Lu Changchun;Zhu Shanshan;Li Yujun;Zhang Zhian;Ma Haili;You Rong;Qin Yanli;Ju Bing;Han Wei;Wang Fang;Chen Xue;Yuan Xiaohua;Ren Xingli;Zhao Lei;Zhang Linghao;Yi Xing;Qiu Yan(Department of Detection,Nanjing Red Cross Blood Center,Nanjing 210003,China;Central Office,Taiyuan Blood Center,Taiyuan 030024,China;Department of Business Management,Harbin Blood Centre,Harbin 150056,China;Department of Detection,Jiangsu Province Blood Center,Nanjing 210042,China;Department of Detection,Ningxia Blood Center,Yinchuan 750011,China;Department of Quality Control,Wuhan Blood Center,Wuhan 430030,China;Administration Office,Yunnan Province Kunming Blood Center,Kunming 650106,China;Administration Office,Jiangxi Province Blood Center,Nanchang 330052,China;Department of Quality Management,Gansu Province Blood Center,Lanzhou 730046,China;Department of Business Management,Shandong Province Blood Center,Jinan 250014,China;Department of Detection,Hebei Province Blood Center,Shijiazhuang 050000,China;Department of Detection,Liaoning Province Blood Center,Shenyang 110044,China;Department of Detection,Chengdu Blood Center,Chengdu 610020,China;Department of Quality Management,Urumqi Blood Center,Urumqi 830000,China;Department of Detection,Inner Mongolia Blood Center,Hohhot 010010,China;Department of Detection,Henan Province Red Cross Blood Center,Zhengzhou 450012,China;Department of Business Management,Xi’an Central Blood Station of Shaanxi Province Blood Center,Xi’an 710000,China;Department of Science and Education Information,Changsha Blood Center,Changsha 410000,China;Central Office,Beijing Red Cross Blood Center,Beijing 100088,China)
出处
《中华实验和临床病毒学杂志》
CAS
CSCD
2022年第4期429-435,共7页
Chinese Journal of Experimental and Clinical Virology
